A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care. We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib, and we are steadily advancing and evolving our product pipeline portfolio, including our lead clinical asset, zanzalintinib, currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of certain forms of colorectal cancer (CRC), as well as the focus of an extensive late-stage clinical development program in other indications. With a rational and disciplined approach to investment, we are leveraging our internal experience and expertise and the strength of strategic partnerships, to identify and pursue opportunities across the landscape of scientific modalities, including small molecules and biotherapeutics, such as antibody-drug conjugates (ADCs).
| Metric | TTM | FY2026 | FY2025 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.3B | 2.3B | 2.2B | 1.8B | 1.6B | 1.4B |
| Net Income | 783M | 783M | 521M | 208M | 182M | 231M |
| EPS | $2.78 | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
| Free Cash Flow | 876M | 876M | 672M | 293M | 335M | 347M |
| ROIC | - | - | 29.6% | 10.3% | 14.7% | 19.1% |
| Gross Margin | 96.4% | 96.4% | 93.9% | 96.0% | 96.4% | 96.3% |
| Debt/Equity | 0.00 | - | 0.32 | 0.10 | 0.08 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 872M | 872M | 605M | 171M | 201M | 287M |
| Operating Margin | 37.6% | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% |
| ROE | 0.0% | - | 23.7% | 8.7% | 7.8% | 11.3% |
| Shares Outstanding | 282M | 282M | 296M | 320M | 326M | 321M |
EXELIXIS, INC. passes 5 of 9 quality checks, suggesting mixed fundamentals.
EXELIXIS, INC. trades at 16.2x trailing earnings, compared to its 15-year median P/E of 22.7x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 13.3x vs a median of 18.2x. The company's 5-year average ROIC is 18.4% with a gross margin of 95.8%. Total shareholder yield (buybacks) is 7.5%. At current prices, the estimated annualized return to fair value is +3.5%.
EXELIXIS, INC. (EXEL) has a current P/E ratio of 16.2, compared to its historical median P/E of 22.7. The stock is currently considered Fair based on its historical valuation range.
EXELIXIS, INC. (EXEL) has a 5-year average return on invested capital (ROIC) of 18.4%. This indicates strong capital allocation and a potential competitive advantage.
EXELIXIS, INC. (EXEL) has a market capitalization of $12.7B. It is classified as a large-cap stock.
EXELIXIS, INC. (EXEL) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 7.49%.
Based on historical P/E analysis, EXELIXIS, INC. (EXEL) appears fair. The current P/E of 16.2 is 29% below its historical median of 22.7. The estimated fair value CAGR (P/E method) is -1.1%.
EXELIXIS, INC. (EXEL) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
EXELIXIS, INC. (EXEL) reported annual revenue of $2.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
EXELIXIS, INC. (EXEL) has a net profit margin of 33.7%. This is a strong margin indicating high profitability.
EXELIXIS, INC. (EXEL) generated $876 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
EXELIXIS, INC. (EXEL) reported earnings per share (EPS) of $2.78 in its most recent fiscal year.
EXELIXIS, INC. (EXEL) has a 5-year average gross margin of 95.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for EXELIXIS, INC. (EXEL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.